Evaluating preference-seeking and aversive qualities of Salvia divinorumand Mitragyna speciosa by Loria, Melissa Jane
University of Mississippi 
eGrove 
Electronic Theses and Dissertations Graduate School 
1-1-2013 
Evaluating preference-seeking and aversive qualities of Salvia 
divinorumand Mitragyna speciosa 
Melissa Jane Loria 
University of Mississippi 
Follow this and additional works at: https://egrove.olemiss.edu/etd 
 Part of the Experimental Analysis of Behavior Commons 
Recommended Citation 
Loria, Melissa Jane, "Evaluating preference-seeking and aversive qualities of Salvia divinorumand 
Mitragyna speciosa" (2013). Electronic Theses and Dissertations. 1221. 
https://egrove.olemiss.edu/etd/1221 
This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been 
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more 
information, please contact egrove@olemiss.edu. 
      
EVALUATING PREFERENCE-SEEKING AND AVERSIVE QUALITIES OF SALVIA 
DIVINORUM AND MITRAGYNA SPECIOSA 
 
 
 
 
 
A Thesis 
presented in partial fulfillment of the requirements 
for the degree of Master of Arts 
in the Department of Psychology 
The University of Mississippi 
 
 
 
 
 
by 
MELISSA JANE LORIA 
May 2013 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright Melissa Jane Loria 2013 
ALL RIGHTS RESERVED 
 
 
 
 ii  
ABSTRACT 
Use of botanicals for self-diagnosed conditions or recreational purposes is increasing. 
Many readily available botanicals are under-researched and little is known about potential 
liabilities. This study sought to utilize Conditioned Place Preference (CPP) to quantify rewarding 
or aversive properties of botanicals and their constituents in rats. This paradigm is based on the 
notion that animals prefer distinct environments previously paired with rewarding drugs. Our 
approach to broadly characterize a botanical and its many constituents entails dose response 
functions of a plant extract, its fractions, and its primary constituent. As a proof of concept, we 
chose two popular botanicals, one expected to produce place preference (Mitragyna speciosa) 
and the other expected to produce place aversion (Salvia divinorum).  Because salvinorin A is 
well characterized as the major psychoactive compound, we did not study an extract fraction for 
S. divinorum. Following apparatus habituation and quantification of baseline compartment 
preference, male Sprague-Dawley rats were given eight drug-compartment conditioning trials 
which involved alternate day pairings of test compound to one compartment and vehicle to the 
other. This was followed by a compartment preference trial conducted under drug-free states. As 
expected, rats showed place preference to mitragynine similar to that of 1mg/kg (+)-
Amphetamine. This effect was much less pronounced with the extract and its fractions. Rats 
showed robust place aversion to both Salvia divinorum and salvinorin A.  These findings suggest 
that products that contain significant quantities of mitragynine pose an abuse liability. 
 
 
 iii  
DEDICATION 
 
 
 
 
 
 
 
For my Mom and Dad, who pushed me, 
For Megan, who saw me through. 
And for Brent, Michael, and Solomon, who kept me smiling.
 
 
 iv  
ACKNOWLEDGEMENTS 
To my committee members—Drs. Kenneth Sufka, Ikhlas Khan, and John Young—, 
thank you for your support, feedback, and time. I will be forever appreciative of your careful 
attention and endless support. 
Special thanks to my advisor, Dr. Sufka. You have been such a wonderful guide and have 
created an atmosphere in which I can challenge myself but also find a sense of brotherhood and 
togetherness.  
Lastly, a big thank you to all the lab members — undergraduate assistants, graduate 
students, and those just dedicating their time. Your constant attention and care for these studies 
were what made this possible.
 
 
 v  
TABLE OF CONTENTS 
ABSTRACT .................................................................................................................................... ii 
DEDICATION ............................................................................................................................... iii 
ACKNOWLEDGEMENTS ........................................................................................................... iv 
TABLE OF CONTENTS ................................................................................................................ v 
INTRODUCTION .......................................................................................................................... 1 
METHODS ..................................................................................................................................... 8 
RESULTS ..................................................................................................................................... 12 
DISCUSSION ............................................................................................................................... 14 
LIST OF REFERENCES .............................................................................................................. 18 
LIST OF APPENDICES ............................................................................................................... 23 
VITA ............................................................................................................................................. 28 
 
 
 
 
 
 
1 
 
INTRODUCTION 
Botanicals are entering the consumer market at a rapid pace and are widely available to 
consumers in a variety of forms. These products are often purchased by consumers to treat 
medical disturbances as well as for recreational purposes (Dennehy, Tsourounis, & Miller, 
2005). In many cases, these plants are on the market with little knowledge of their range of 
action, toxicity, and abuse potential. However, consumers are comforted by the “all natural” 
label and continue to use the products because they falsely believe that this label indicates safety 
and a lack of physical and psychological health risks (Marcus & Grollman, 2002). Botanicals can 
be dangerously complex due to their wide arrays of constituents. While one effect of a botanical 
may be understood, numerous other constituents present in the same plant may lead to harmful 
effects. Even if the activity of the primary active constituent is understood, this knowledge may 
not be enough to have a full understanding of the plant’s potential toxicity risks. Wide 
availability of under-researched botanical compounds could easily lead to a plethora of 
physiological and psychological disturbances in an unsuspecting group of consumers.  
Kava-kava is an example of a botanical that found its way into the consumer market and 
led to severe toxicity in some users. The compound is extracted from the roots of Piper 
mesthysticum, a kava plant native to the South Pacific Oceanic Islands. Islanders traditionally 
consumed the drink for its intoxicating effects. Expansive knowledge on traditional use led to no 
worrisome side effects or glaring health risks (Whitton et al., 2003). 
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Kava-kava gained popularity in the West and modern consumers used it to aid in sleep, 
reduce anxiety, and as an alternative intoxicant to alcohol (Whitton et al., 2003). The Drug 
Enforcement Administration’s Office of Diversion Control states on its Drug and Chemicals of 
Concern list that kava is sold as a dietary supplement and serves as a natural alternative to anti-
anxiety medications. They also state that, while research on illicit use of kava is purely 
anecdotal, consumers are utilizing the plant for relaxation and its mild euphoric states. In 
addition, it is often used as a sleep aid ("Drugs and Chemicals of Concern: Kava"). 
The increased popularity of kava-kava was not without adverse consequences. 
Hepatotoxicity has been reported in a number of individuals regularly using kava (Humberston, 
Akhtar, & Krenzelok, 2003; Teschke, Schwarzenboeck, & Akinci, 2008). More specifically, 
liver damage, including hepatitis and cirrhosis, and full liver failure have been linked to kava use 
("Drugs and Chemicals of Concern: Kava").   
Observations of toxicity associated with kava-kava are not surprising given current 
analysis of this product. In an in vitro model of liver toxicity, kava extracts were found to cause 
toxic effects (Lüde et al., 2008). Further, kavalactones were shown to disrupt liver detoxification 
pathways due to inhibition of cytochrome P450 activity in addition to reducing the natural levels 
of glutathione in the liver (Clouatre, 2004).  
Present-day consumers are engaged in self-diagnosing and using wholly unregulated 
botanicals for the treatment of a variety of maladies. They are being prescribed and self-
prescribing unstandardized botanicals without any empirical evidence for efficacy or any 
empirical knowledge of potential toxicity. Further, no systematic studies have evaluated proper 
dosing and possible drug-drug interactions in many of these compounds. These issues alone 
would justify the need of a scientific approach for systematically studying these botanicals.  
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The recreational use of botanicals marketed to produce pleasurable psychoactive effects 
is another major concern. These botanicals are widely available at local “head shops” and 
through online botanical pharmacies (Dennehy, Tsourounis, & Miller, 2005). One attraction to 
the use of understudied botanicals as recreational compounds is that they are unregulated. As 
with botanicals used medicinally, recreational botanicals have not been properly evaluated for 
abuse liability or for toxicity associated with the product.  
Animal models are often used to evaluate properties of drug substances. A common 
animal model used to identify abuse potential is the Conditioned Place Preference paradigm 
(CPP). CPP is based on the notion that animals prefer environments previously paired with 
positively reinforcing drugs (Bardo & Bevins, 2000). The paradigm has three phases: 1) 
habituation and initial compartment preference, 2) conditioning through pairing drug/no-drug 
treatments in chambers with distinct stimuli, and 3) testing the conditioned animal under drug-
free states. Preference is determined by animals spending significantly more time in the drug-
paired chamber and aversion is determined by animals spending significantly less time in the 
drug-paired chamber.  
Because botanical products typically contain a large array of constituents, determining 
abuse potential is more challenging. This is due to the possibility of the plant containing more 
than one psychoactive constituent with rewarding or antagonistic effects. For example, a 
botanical may have a primary active constituent with abuse potential, but in combination with 
antagonistic constituents present, it will not indicate preference. Thus, studying entire plants for 
abuse potential could lead to false negatives in this paradigm. On the other hand, studying 
individual constituents could also lead to false negatives. This could occur if preference relies on 
the synergistic effects of multiple constituents.   
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A solution to the previously outlined problem is a methodical approach in which the 
whole plant extract, a fraction of the extract, and the plant’s believed active constituent are 
evaluated. With this approach, the paradigm can identify a) if the believed active constituent is 
wholly responsible for a plant’s psychoactive effects, b) if there are further rewarding or aversive 
qualities in other constituents, and c) if the constituents responsible for alternative qualities are 
present in the selected fraction. The process of identifying other psychoactive constituents can be 
narrowed down by evaluating whether the fraction shows the same qualities of the whole plant 
extract. If so, the fraction will be known to contain the responsible constituent. If not, further 
evaluation of constituents present in the whole plant extract will be necessary. In either case, it 
will be highlighted that there are additional psychoactive properties in the plant. 
As a proof of concept, two products were evaluated using this method: one expected to 
produce place preference and another expected to produce place aversion. These expectations 
were developed based on human responses to recreational or medicinal use, broad historical 
backgrounds and traditional uses, and an understanding of receptor binding activity in the two 
plants. Of the many available, we selected Salvia divinorum (S. divinorum) to serve as the 
aversive botanical and Mitragyna speciosa (M. speciosa) to serve as the rewarding botanical.  
S. divinorum, a member of the Sage family and native to Mexico, is also known as 
“Diviner’s Sage,” “Mystic Sage,” and “Magic Mint” (Babu, McCurdy, & Boyer, 2008). S. 
divinorum was traditionally consumed by means of water infusion (Valdéz III, Díaz, & Paul, 
1983). The Drug Enforcement Administration has listed S. divinorum and its active constituent, 
salvinorin A, on the drug or chemical of concern list. Several states have already placed 
regulatory control on both S. divinorum and salvinorin A ("Drugs and Chemicals of Concern: 
Salvia Divinorum,"). Traditionally, the Mazatec tribe of Oaxaca, Mexico used S. divinorum for 
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both the divination of shamans through hallucinations as well as for curing a variety of 
physiological and psychological ailments in community members (Valdéz III et al., 1983). In the 
1960s, nearly all Mazatec tribe members claimed to be aware of the botanical (Wasson, 1962). 
Today, S. divinorum is in the spotlight because it is marketed as a legal hallucinogen and 
is readily available to consumers (Griffin, Miller, & Khey, 2008; Hillebrand, Olszewski, & 
Sedefov, 2010). Use of the botanical is growing rapidly in the young adult population with 5.9% 
of high schools seniors reporting to have used S. divinorum in the last year ("Drugs and 
Chemicals of Concern: Salvia Divinorum,"). In states without restrictions, S. divinorum can be 
purchased at “head shops.” In addition, it is one of the most widely available herbal dietary 
supplements suggested for recreational use on the internet (Dennehy et al., 2005). Consumers are 
now using the plant by means of smoking the leaves or smoking pure salvinorin A ("Drugs and 
Chemicals of Concern: Salvia Divinorum,").  
Salvinorin A is the known active alkaloid and other constituents in the plant are not 
believed to have psychoactive properties ("Drugs and Chemicals of Concern: Salvia 
Divinorum,"). Receptor binding studies have demonstrated that salvinorin A acts as a κ-opioid 
receptor agonist (Chavkin et al., 2004). Previous studies have shown that κ-agonists act as a 
psychotomimetic in humans and, not surprisingly, cause place aversion in rodent models (Mucha 
& Herz, 1985; Pfeiffer et al., 1986). Consistent with these findings, salvinorin A has been shown 
to produce place aversion in mice (Zhang et al., 2005).  
M. speciosa, a member of the Rubiaceae family and native to Southeastern Asia, is 
widely known as “Kratom,” but is also called “Biak-biak” and “Ketum” in Malaysia (Ahmad & 
Aziz, 2012). Consumption of the plant is primarily achieved through chewing fresh leaves but 
some users grind and swallow leaves or use the leaves in a tea (Assanangkornchai et al., 2007). 
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The Drug Enforcement Administration has listed mitragynine as the primary active alkaloid in 
M. speciosa. The plant has long been a part of southern Thailand history and traditions with its 
use first recorded in 1935. The botanical was medicinally used for pain, infection, coughing, and 
diarrhea (for review: Hassan et al., 2013). 
A recent survey in northern Thailand revealed that most local M. speciosa users were 
consuming the plant to increase physical endurance for long, physically demanding work days 
(Ahmad & Aziz, 2012). Currently, western consumers have begun to purchase the botanical for 
its stimulant like effects at low doses and its opiate-like and sedative effects at higher doses 
("Drugs and Chemicals of Concern: Mitragyna speciosa,").  These recreational uses of the plant 
are not isolated to the West; use amongst young people in Thailand is increasing due to the 
introduction of a homemade cocktail called 4x100. The cocktail includes boiled M. speciosa 
leaves, cough syrup, and Coca-Cola (Tanguay, 2011).  
Mitragynine is the major active chemical constituent found in M. speciosa and is not 
found in any other Mitragyna plants (Shellard, 1974). Mitragynine has been shown to have high 
affinity to the µ-opioid receptor (Watanabe et al., 1997; Yamamoto et al., 1999). Previous studies 
have shown that µ-opioid receptor agonists play a role in addiction (for review Koob, Sanna, & 
Bloom, 1998). A study looking at current users revealed that 88% of daily users were unable to 
stop using the plant (Ahmad & Aziz, 2012).  Not surprisingly, µ-opioid receptor agonists have 
been shown to produce place preference in a rodent model (Bardo, Rowlett, & Harris, 1995).  
In the present project, rewarding and aversive properties of S. divinorum and M. speciosa 
will be characterized using the CPP model. The full plant extract and the major psychoactive 
constituent will be evaluated in both plants in addition to a fraction of the constituents in M. 
speciosa. Salvinorin A’s CNS action and behavioral effects are well understood, but there is a 
  
7 
 
chance that other minor constituents possess antagonistic or synergistic effects. In testing the 
whole plant extract, the presence of any unknown psychoactive components or potential 
synergistic effects will be realized. Thus, to reduce animal use, a fraction of S. divinorum will not 
be evaluated. 
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METHODS 
 
Male Sprague Dawley rats (175-200 g, 6-7 weeks old; Harlan, Indianapolis, IN) served as 
subjects for these experiments.  Animals were housed in pairs and maintained under a 12-h 
light/dark cycle in a temperature and humidity controlled vivarium.  Food and water were 
available ad libitum.  Animals had a 3-day period in which they were not tested but handled by 
experimenters to acclimate to the vivarium and to reduce experimenter-related stress. In both 
experiments, conditions had a sample size of 7-10.  
Five place preference chambers (Model MED CPP RS; Med Associates, St. Albans, VT) 
were used for the experiment. Each chamber has three compartments: two stimulus-distinct, 
drug-conditioning chambers and a centralized “neutral” start chamber. Guillotine doors provide 
access between the start chamber and the conditioning chambers. Each conditioning chamber 
measures 30 x 30 x 30 cm. The stimuli of the two conditioning compartments are distinct on the 
basis of visual and tactile cues. One compartment is white with wire mesh floor and the other 
compartment is black with a metal rod floor. The center chamber measures 15 x 30 x 30 cm and 
is gray with a solid floor.  
The Conditioned Place Preference procedure (Bardo & Bevins, 2000) involves four 
phases: 1) a 15 minute apparatus habituation trial under drug free states, 2) a 15 minute baseline 
preference trial under drug free states, 3) eight 30 minute drug/drug-free conditioning trials, and 
4) a final 15 minute place preference trial under drug-free states. Animals had access to the entire 
place preference apparatus during the habituation, baseline, and final preference trials. Baseline 
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preference trials were used to identify any initial compartment bias to aid in assigning 
compound pairing conditions. The conditioning phase was characterized by alternate day 
pairings of test compound in one compartment (S+ compartment) and vehicle in the other (S- 
compartment). S+ was determined by selecting the non-preferred side if the compound was 
expected to produce CPP and the preferred side for compounds expected to produce CPA. Test 
apparatus was thoroughly cleaned after each trial. Compound or vehicle was administered via 
intraperitoneal (IP) injection immediately preceding each conditioning trial. Conditioning trials 
were counter-balanced for order (drug/vehicle) within treatments conditions. Compartment and 
compound/vehicle assignments were also counter-balanced and assigned based on initial 
preference scores. Following the final phase of the procedure, the change in time spent in the S+ 
compartment pre- and post-conditioning was analyzed.  
 
Drug Probes 
Experiment I 
Morphine has previously been used as a compound to establish preference seeking 
behavior in this paradigm (for review: Tzschentke, 2007). In this experiment, 10 mg/kg of 
Morphine served as a “positive” control for quantifying conditioned place preference (CPP).  
Haloperidol, on the other hand, has previously been used as a compound to establish aversion in 
this paradigm (for review: Tzschetke, 1998). 1 mg/kg of Haloperidol served as the “negative” 
control for quantifying conditioned place aversion (CPA). Morphine was diluted in physiological 
saline. 50% DMSO and 50% saline were used as the vehicle for haloperidol (1.0 ml/kg).  
Salvia divinorum extract (10, 30, 100 mg/kg) was prepared by exhaustive extraction of 
dry plant material with ethanol. The extract was filtered and then concentrated.  Because it is 
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well-established that the psychoactive properties of S. divinorum are mediated by salvinorin A, 
we opted to not include analysis of a S. divinorum fraction. Salvinorin A (0.1, 0.3, 1.0 mg/kg) 
was isolated from S. divinorum leaves as previously described (Munro & Rizzacasa, 2003). 
Briefly, S. divinorum leaves were extracted with acetone and subsequently recrystallized from 
95% ethanol to yield 99% (HPLC) pure salvinorin A. The salvinorin A doses selected were 
based on previously published studies in rodent models (McCurdy et al, 2006) and, for S. 
divinorum, dosing equivalence based on concentrations of salvinorin A in the extract. 10% 
DMSO and 10% Tween80 were used as the vehicle for S. divinorum and salvinorin A (1.0 
ml/kg).  
 
Experiment II 
In the second experiment, d-amphetamine (1 mg/kg), instead of morphine, served as the 
“positive” control. D-amphetamine has previously been used to establish preference seeking 
behavior in this paradigm (for review: Tzschetke, 1998). This was used because it was 
anticipated that M. speciosa may show some psychostimulant properties. Haloperidol (0.8 
mg/kg) served as the “negative” control. Amphetamine was diluted in physiological saline. 50% 
DMSO and 50% saline were used as the vehicle for haloperidol (1.0 ml/kg). 
The leaves of M. speciosa (Voucher # 12433) were exhaustively extracted with methanol 
and the solvent was removed under reduced pressure to yield a dried extract. An aliquot was 
suspended in 5% HCl in water and extracted with ethyl acetate. The water-soluble part was 
basified (pH 9-10) with liquid ammonia and extracted with ethyl acetate. The ethyl acetate-
soluble part, separated from basic media, was dried under reduced pressure to get an alkaloid 
enrich fraction. Mitragynine (97% pure) was isolated from the alkaloid enrich fraction by 
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repeated column chromatogaraphy over silica gel using chloroform/methanol (9:1) and 
hexanes/acetone/liq. ammonia (210:90:1) solvent systems. From these processes, M. speciosa 
extract (750, 1500, 4500 mg/kg), alkaloid enrich fraction (187.5, 375, 1125 mg/kg) and 
mitragynine (75, 150, and 450 mg/kg) were used in this study. The mitragynine doses selected 
were based on previously published studies in rodent models (Sabetghadam et al, 2013) and for 
M. speciosa, the dosing equivalence based on concentrations of mitragynine in the extract.  In 
this study, S(+)-amphetamine (1 mg/kg in saline) served as the positive control for CPP and 
haloperidol (0.8 mg/kg) served as the negative control for CPA. Two vehicles were used and 
tested in this study. 20% Tween80 and saline were used as the vehicle for M. speciosa, the 
fraction, and mitragynine.  
 
Data Acquistion and Analyses 
All data acquisition was handled by infrared photo-beam detection via MED-PC® IV and 
analyses were conducted using SPSS statistical software. Group differences (preference/aversion 
scores) were analyzed using one-way ANOVAs. Preference scores are defined as (time spent in 
S+ post-conditioning – time spend in S+ pre-conditioning). A small change in relative time 
between S+ and S- chambers is expected in the vehicle groups simply due to repeated exposures. 
Relevant post hoc analyses will be performed using Fisher’s LSD. Rewarding or aversive 
properties of compounds were determined by a statistically significant (p < 0.05) increase or 
decrease in preference scores relative to vehicle treated rats.
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RESULTS 
Experiment 1 
To reduce the number of animals used, 5 vehicle animals received the haloperidol vehicle 
and 5 received the S. divinorum vehicle. A one-way ANOVA comparing preference scores was 
conducted and revealed no significant differences between these two groups. Therefore, vehicle 
groups were combined prior to computation of the analyses detailed below.  
Preference scores for Experiment I are summarized in Figure 1. As expected, vehicle 
group preference scores changed minimally, increasing only +23 seconds. This minor change 
score is now depicted as the x-axis in Figure 1. Morphine treated animals tended to have higher 
preference scores and haloperidol treated animals tended to have lower preference scores 
compared to vehicle treated groups. In general, both S. divinorum and salvinorin A show a 
pattern of place aversion across all doses tested. To illustrate the place preference/aversion 
effects across treatment groups, a one-way ANOVA was performed on these data and revealed a 
significant main effect for treatment condition, F(8,73) = 3.986, p = 0.001. Post-hoc analyses 
revealed that mean preference scores for the morphine (positive control) condition did not 
significantly differ from the vehicle. The mean preference score for haloperidol was not, but 
approached being, significantly lower than the vehicle group, (p = 0.083). Mean preference 
scores for 10 and 100 mg/kg S. divinorum were statistically significantly lower than the vehicle, 
(p = 0.022 and p < 0.001). The 30 mg/kg S. divinorum extract condition was not, but approached 
being, significantly lower than the vehicle group, (p = 0.073).  The mean preference scores of the 
0.3 and 1.0 mg/kg salvinorin A groups were statistically significantly lower than the vehicle 
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group, (p = 0.004 and p = 0.004). The mean preference score of the 0.1 mg/kg salvinorin 
A group was in the direction of being significantly lower than the vehicle, (p = 0.051).  
 
Experiment 2 
To reduce the number of animals used, 5 vehicle animals received the haloperidol vehicle 
and 5 received the M. speciosa vehicle. A one-way ANOVA comparing preference scores was 
conducted and revealed no significant differences between these two groups. Therefore, vehicle 
groups were combined prior to computation of the analyses detailed below. 
Preference scores for Experiment II are summarized in Figure 2. As expected, vehicle 
group preference scores changed minimally, increasing approximately +30 seconds. This minor 
change score is now depicted as the x-axis in Figure 2. D-Amphetamine treated animals have 
higher preference scores and haloperidol treated animals tended to have lower preference scores. 
In general, the M. speciosa extract, its fraction, and its active, mitragynine, show a pattern of 
place preference across nearly all doses. To illustrate the place preference/aversion effects across 
treatment groups, a one-way ANOVA was performed on these data and revealed a significant 
main effect for treatment condition, F(11,101) = 2.97, p = 0.002. Post-hoc analyses revealed that 
the mean preference score for d-Amphetamine (positive control) condition significantly differed 
from the vehicle group, (p = 0.016). The mean preference score of haloperidol was in the 
direction of being significantly lower than the vehicle, (p = 0.09). Mean preference scores for 75 
and 450 mg/kg mitragynine groups were significantly higher than the vehicle, (p = 0.027 and p = 
0.026). Mean preference score for 150 mg/kg mitragynine group was not, but approached being, 
significantly higher than the vehicle group, (p = 0.076).  
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DISCUSSION 
Experiment 1 
The goal of the first experiment was to characterize rewarding or aversive properties of S. 
divinorum and salvinorin A. Following apparatus habituation and quantification of baseline 
compartment preference, male Sprague-Dawley rats were given eight drug-compartment 
conditioning trials, which involved alternate day pairings of test compound to one compartment 
(S+) and vehicle to the other (S-). This was followed by a compartment preference trial 
conducted under drug-free states. Preference was defined by animals spending significantly more 
time in the drug conditioned chamber after conditioning.  
Vehicle animals spent approximately the same amount of time in the S+ chamber before 
and after conditioning. This indicates that animals do not show compartment bias to the 
apparatus after repeated conditioning trials. Surprisingly, morphine, our positive control, failed 
to show place preference. However, the literature on morphine place preference is equivocal. 
Some labs report place preference across a range of doses whereas others do not (i.e. 1 – 10 
mg/kg). Two factors may have played a role in this finding. First, the dose may have been too 
high (10 mg/kg) as this appears to produce more mixed results than lower doses (for review: 
Tzschentke, 2007). Secondly, the loss of three data points certainly compromised statistical 
power. In this study, 1 mg/kg haloperidol produced modest place aversion. The lack of 
significance was potentially due to too high a dose. The earliest study showing CPA with 
haloperidol used a much lower dose of 0.1 mg/kg in mice (Risinger, Dickinson & Cunningham, 
1992). Thus, haloperidol dosing was lowered to 0.8 mg/kg for the second experiment.  
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 Salvinorin A showed a pattern of place aversion across all doses. This is not surprising as 
previous research shows salvinorin A producing place aversion (Zhang, Butelman, Schlussman, 
Ho, & Kreek, 2005). Salvinorin A is a κ-opioid receptor agonist and κ-agonists are known to 
produce robust place aversion in the CPP paradigm (Mucha & Herz, 1985). S. divinorum also 
produced place aversion approximate to that of salvinorin A. This is not surprising as salvinorin 
A is the major constituent in S. divinorum ("Drugs and Chemicals of Concern: Salvia 
Divinorum,"). These observations suggest that salvinorin A is also the main constituent 
responsible for the place aversion observed with administration of S. divinorum. In previous 
research, compounds that produce CPA lack abuse potential (Sufka, 1994). Collectively, these 
findings indicate that both S. divinorum and salvinorin A lack abuse potential. 
 
Experiment 2 
The goal of the second experiment was to characterize rewarding or aversive properties 
of M. speciosa, a fraction of the botanical, and its active, mitragynine. Following apparatus 
habituation and quantification of baseline compartment preference, male Sprague-Dawley rats 
were given eight drug-compartment conditioning trials which involved alternate day pairings of 
test compound to one compartment and vehicle to the other. This was followed by a 
compartment preference trial conducted under drug-free states. Preference was defined by 
animals spending significantly more time in the drug conditioned chamber after conditioning. 
Vehicle animals spent approximately the same amount of time in the S+ chamber before 
and after conditioning. This indicates that animals do not show compartment bias to the 
apparatus after repeated conditioning trials. Consistent with the literature, d-amphetmine, our 
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positive control, produced robust place preference (for review see: (Tzschentke, 2007)). Using a 
slightly lower dose of haloperidol, our negative control, produced marginal place aversion.  
Mitragynine shows place preference across doses with robust effects seen at the low and 
high doses, indicative of abuse potential. This is not surprising, as previous research shows that 
mitragynine displays affinity to µ-opioid receptors. Compounds with affinity to µ-opioid 
receptors are known to produce robust place preference (for review see: Hassan et al., 2012). 
These findings are also consistent with anecdotal evidence suggesting that consumers have 
difficulty stopping use of the plant (Ahmad & Aziz, 2012). 
The whole plant extract of M. speciosa shows a pattern of place preference but does not 
reach significance at any of the doses. The fraction of the plant, however, shows far less 
rewarding activity than the whole plant extract and mitragynine. In the doses of both the extract 
and the fraction, the amount of mitragynine mirrors the doses used when testing the active 
constituent alone. With the amount of mitragynine steady, appearance of significant CPP in 
mitragynine alone but not in the extract or fraction raises questions. It is suspected that there may 
be a constituent present in both the whole plant extract and the fraction that is either 1) producing 
place aversion thus mediating the preference caused by mitragynine or 2) antagonizing the 
activity of mitragynine. 
 
Future studies 
 Botanicals typically contain a large variety of constituents that may possess a diverse 
array of activity. Because of this complexity, the study of botanicals can lead to false negatives 
when lacking methods that allow for a broad analysis of the plant’s psychoactive properties. An 
example of this problem can be observed in the current evaluation of M. speciosa, where results 
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were not consistent across the whole plant extract, fraction, and mitragynine. The current study 
utilized a novel approach in which three doses of the entire plant extract, a fraction of the active 
constituents, and the plant’s primary active constituent were tested. This approach allows for a 
more complete evaluation of the large array of constituents comprising a botanical. Researchers 
can identify a) if the believed active constituent is wholly responsible for a plant’s psychoactive 
effects, b) if there are further rewarding or aversive qualities in other constituents, and c) if the 
constituents responsible for alternative qualities are present in the selected fraction. Researchers 
may want to adopt this 3-tiered approach in future research evaluating botanical products that are 
suspect for abuse liability and other psychoactive qualities.  
Given the varying results of M. speciosa, its fraction, and mitragynine, further evaluation 
of the plant’s constituents would make an interesting follow up study. The current findings 
support evidence of other active constituents with aversive qualities or constituents synergistic to 
mitragynine. Paynantheine and Speciogynine make up 9 and 7% of the plant, respectively, and 
may be valuable to investigate. In addition, 7-hydroxymitragynine has been identified as a minor 
constituent, comprising 2% of the plant, and may be a good option to study (for review see: 
(Hassan et al., 2013)). Research evaluating alternate constituents of M. speciosa, such as 7-
hydroxymitragynine, would help researchers to gain a broader understanding of psychoactive 
qualities of the botanical. If there is a constituent that is not aversive and synergistically interacts 
with mitragynine’s rewarding effects to reduce CPA, this could open new doors in the study of 
addiction. This constituent could offer insight in attenuating addictive qualities in other drugs of 
abuse. 
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FIGURE CAPTIONS 
Figure 1. The effects of S. divinorum and salvinorin A on place preference. Values represent 
mean change in seconds (±SEM) spent in S+ chamber before and after drug-conditioning during 
a 15 min drug-free test. Solid horizontal line reflects the mean preference score for the vehicle 
group and is provided for comparative purposes. Scores above baseline signify place preference 
while scores below baseline signify place aversion. * indicates a significant difference from the 
vehicle group. Sample sizes were 7-10.  
 
Figure 2. The effects of M. speciosa, its fraction, and mitragynine on place preference. Values 
represent mean change in seconds (±SEM) spent in S+ chamber before and after drug-
conditioning during a 15 min drug-free test. Solid horizontal line reflects the mean preference 
score for the vehicle group and is provided for comparative purposes. Significant conditions that 
are higher than the baseline signify preference while significant conditions that drop lower than 
the baseline signify aversion. . * indicates a significant difference from the vehicle group.  
Sample sizes were 9-10.  
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